Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carboplatin: a new cisplatin analog.

D M Woloschuk1, J M Pruemer, R J Cluxton

  • 1University of Cincinnati Hospital, OH.

Drug Intelligence & Clinical Pharmacy
|November 1, 1988
PubMed
Summary

Carboplatin shows promise in treating ovarian carcinoma, head and neck cancer, and small-cell lung cancer with fewer toxic side effects than cisplatin. Further trials are needed to confirm its role as a cisplatin replacement.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In-vitro stability of porcine factor VIII (Hyate:C(®) ).

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Impact of school-based health centers on children with asthma.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine·2005
Same author

Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors.

American journal of hematology·1997
Same author

Preventing medication errors in cancer chemotherapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1996
Same author

Drug precipitation and peristaltic pumps.

American journal of hospital pharmacy·1994
Same author

High technology drugs for cancer: the decision process for adding to a formulary.

PharmacoEconomics·1993

Area of Science:

  • Medical Oncology
  • Pharmacology

Background:

  • Carboplatin is a novel antineoplastic agent.
  • It exhibits antitumor activity comparable to cisplatin.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of carboplatin.
  • To identify patient populations who may benefit from carboplatin therapy.

Main Methods:

  • Clinical activity assessment in ovarian carcinoma, head and neck cancer, and small-cell lung cancer.
  • Analysis of carboplatin's pharmacokinetic profile and toxicity.
  • Correlation of renal platinum clearance with creatinine clearance.

Main Results:

  • Carboplatin demonstrates activity in specific cancers but causes dose-limiting myelosuppression.
  • It is less nephrotoxic, ototoxic, and neurotoxic compared to cisplatin.
  • Renal clearance of platinum is linked to creatinine clearance.

Conclusions:

  • Carboplatin is a viable option for patients with impaired renal function or those intolerant to cisplatin's hydration requirements.
  • It may be particularly beneficial for patients at high risk of cisplatin-induced ototoxicity or neurotoxicity.
  • Large-scale comparative trials are necessary to establish carboplatin as a cisplatin substitute.

Related Experiment Videos